WO2011035569A1 - Process for manufacture of n-acylbphenyl alanine - Google Patents

Process for manufacture of n-acylbphenyl alanine Download PDF

Info

Publication number
WO2011035569A1
WO2011035569A1 PCT/CN2010/071243 CN2010071243W WO2011035569A1 WO 2011035569 A1 WO2011035569 A1 WO 2011035569A1 CN 2010071243 W CN2010071243 W CN 2010071243W WO 2011035569 A1 WO2011035569 A1 WO 2011035569A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
salt
acid
preparing
Prior art date
Application number
PCT/CN2010/071243
Other languages
French (fr)
Inventor
Guoliang Zhu
Desong Shi
Junhui Wei
Fengfeng Tao
Original Assignee
Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2009/074125 external-priority patent/WO2010034236A1/en
Priority to MX2012003488A priority Critical patent/MX2012003488A/en
Priority to ES10818263.5T priority patent/ES2627060T3/en
Priority to IN1968DEN2012 priority patent/IN2012DN01968A/en
Priority to AU2010297892A priority patent/AU2010297892B2/en
Priority to EP10818263.5A priority patent/EP2480523B1/en
Priority to KR1020167036201A priority patent/KR101821090B1/en
Priority to CN201080042243.1A priority patent/CN102639486B/en
Application filed by Zhejiang Jiuzhou Pharmaceutical Co., Ltd., Novartis Ag filed Critical Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
Priority to CA2772681A priority patent/CA2772681C/en
Priority to JP2012530106A priority patent/JP5894531B2/en
Priority to RU2012116208/04A priority patent/RU2534619C2/en
Priority to BR112012006406A priority patent/BR112012006406A2/en
Priority to US13/497,544 priority patent/US20130172572A1/en
Publication of WO2011035569A1 publication Critical patent/WO2011035569A1/en
Priority to US14/163,526 priority patent/US9242927B2/en
Priority to US14/990,832 priority patent/US20160115118A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18Oxygen atoms
    • C07D263/20Oxygen atoms attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/51Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/64Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/83Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an acyclic saturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/64Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/87Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings

Definitions

  • the invention relates to a novel process, novel process steps and novel intermediates useful in the synthesis of pharmaceutically active compounds, in particular neutral endopeptidase (NEP) inhibitors.
  • NEP neutral endopeptidase
  • the present invention relates to a method to prepare N-acyl derivatives of biphenyl alanine.
  • N-acyl derivatives of biphenyl alanine are key intermediates in the synthesis of pharmaceutically active compounds, in particular neutral endopeptidase (NEP) inhibitors, such as those described in U.S. Patent No. 4,722,810, U.S. Patent No. 5,223,516, U.S. Patent No. 4,610,816, U.S. Patent No.
  • NEP neutral endopeptidase
  • biphenyl alanine derivatives typically use expensive starting materials such as non-natural D-tyrosine. Moreover, said methods require the use of trifluoromethanesulfonic anhydride, which is also expensive, to activate the phenolic hydroxyl in order to carry out the aryl coupling reaction leading to the desired biphenyl structure.
  • trifluoromethanesulfonic anhydride which is also expensive, to activate the phenolic hydroxyl in order to carry out the aryl coupling reaction leading to the desired biphenyl structure.
  • This invention provides a method for preparing a N-acylbiphenyl alanine of formula (3), as defined herein.
  • the new process, according to the present invention, for producing compounds according to formula (3) is summarized in Scheme 2.
  • a compound of formula (1) is obtained.
  • Said compound of formula (1) is next converted into a compound of formula (2), as defined herein, which in turn is hydrogenated, for example with hydrogen and palladium on charcoal, to provide the compound of formula (3).
  • a compound of formula (3) can be converted into a neutral endopeptidase (NEP) inhibitors, for example, as described in the Journal of Medicinal Chemistry, 1995, Vol. 38, No. 10, 1691, and the patent documents cited hereinbefore, the disclosure for each of which is incorporated by reference
  • NEP neutral endopeptidase
  • Step a
  • the present invention relates to a method for preparing a compound of formula (1-a), or salt thereof, preferably wherein the compound of formula (1-a) is of the formula (1),
  • Rl is Ci_ 7 alkyl, preferably methyl, or C 6 _ioaryl, preferably phenyl,
  • Rl is as defined for the compound of formula (1-a),
  • R2 is Ci_ 7 alkyl, preferably methyl or propyl, most preferably methyl or ethyl,
  • solvents generally known in the art, for example, in the presence of a solvent, (named solvent I), selected from benzene, toluene, xylene, chlorobenzene, dichlorobenzene, nitrobenzene, heptane, acetic acid, propionic acid, isobutyric acid, n-butyric acid, acetic anhydride or propionic anhydride.
  • solvent I selected from benzene, toluene, xylene, chlorobenzene, dichlorobenzene, nitrobenzene, heptane, acetic acid, propionic acid, isobutyric acid, n-butyric acid, acetic anhydride or propionic anhydride.
  • anhydride (B) is acetic anhydride or propionic anhydride.
  • under alkaline conditions means that the step requires a base.
  • said base is selected from triethylamine, pyridine, N-methylpyrrole, N-methylmorpholine, sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, sodium acetate, potassium acetate, sodium propionate, or potassium propionate.
  • step a is carried out at a reaction temperature of from 80 deg C to reflux, preferably, with a reaction time of 0.5 to 48 hours.
  • the molar ratio of said biphenyl formaldehyde : said N-acylglycine (A) : said anhydride (B) : said base is 1.0 : (0.7 to 5.0) : (1.0 to 6.0) : (0.05 to 2.00); the amount of said solvent I is 0 to 20 times the weight of feed amount of said biphenyl formaldehyde.
  • Step b
  • the present invention relates to a method for preparing a compound of formula (2-a), or salt thereof,
  • Rl is Ci_ 7 alkyl, preferably methyl, or C 6 -ioaryl, preferably phi
  • the reactions described above can be carried out in solvents generally known in the art, for example, in the presence of a solvent, (named solvent II), selected from water, ethanol, methanol, isopropanol, propanol, ethyl acetate, isopropyl acetate, ethyl propionate, acetone, butanone, methyl isobutyl ketone, tetrahydrofuran, 1,4-dioxane, N, N-dimethyl formamide, or N-methylpyrrole.
  • a solvent selected from water, ethanol, methanol, isopropanol, propanol, ethyl acetate, isopropyl acetate, ethyl propionate, acetone, butanone, methyl isobutyl ketone, tetrahydrofuran, 1,4-dioxane, N, N-dimethyl formamide, or N-methylpyrrole.
  • step b is carried out at a reaction temperature of from room temperature to reflux.
  • step c is carried out at a reaction temperature of from room temperature to reflux.
  • the present invention relates to a method for preparing a compound of formula (3), or salt thereof, preferably wherein the compound of formula (3) is of the formula (3-a),
  • Rl is Ci_ 7 alkyl, preferably methyl, or C 6 -ioaryl, preferably phenyl, comprising
  • Rl is Ci_ 7 alkyl, preferably methyl, or C 6 -ioaryl, preferably phenyl,
  • Hydrogenation conditions are well-known in the art and thus refer to the use of hydrogen and a transition metal catalyst, for example, as described in Section B.3.3 in WO2009/090251, which is incorporated herein by reference.
  • the transition metal catalyst is palladium, preferably palladium on charcoal, preferably containing 1% to 20% palladium by weight.
  • the hydrogenation takes place with hydrogen in the presence of a transition metal catalyst comprising an organometallic complex and a chiral ligand, for example as described in Section C.2 in WO2009/090251, which is incorporated herein by reference.
  • solvent III selected from ethanol, methanol, ethyl acetate, N, N-dimethyl formamide, N-methylpyrrole and tetrahydrofuran.
  • the weight of feed amount of said solvent III is 5 to 50 times of the amount of the compound of formula (1) [named product 1] in step a.
  • the amount of palladium on charcoal is 0.1% to 20%> of the compound of formula (2) [named product 2] in step b by weight.
  • step c glacial acetic acid is also added in order to maintain acidic conditions.
  • the reaction temperature is of from 20 deg C to 150 deg C.
  • the pressure of hydrogen is 0.2 MPa to 10.0 MPa.
  • the present invention relates to a method for preparing a compound of formula (3), as defined herein, or salt thereof, comprising
  • step a) step a), as described above;
  • step c) as described above.
  • the present invention relates to a method for preparing a compound of formula (3), as defined herein, or salt thereof, comprising
  • Embodiment [1] A method for preparing N-acylbiphenyl alanine which is characterized by the following steps:
  • Rl is a straight-chain or branched-chain alkyl or aryl and R2 is a methyl or ethyl.
  • Embodiment [2] A method for preparing N-acylbiphenyl alanine according to embodiment [1], characterized in that for step a, the molar ratio of said biphenyl formaldehyde: said N-acylglycine: said anhydride: said base is 1.0: (0.7 to 5.0): (1.0 to 6.0): (0.05 to 2.00), and the amount of said solvent I is 0 to 20 times the weight of feed amount of said biphenyl formaldehyde.
  • Embodiment [3] A method for preparing N-acylbiphenyl alanine according to embodiment [1], characterized in that for step a, said solvent I is selected from benzene, toluene, xylene, chlorobenzene, dichlorobenzene, nitrobenzene, heptane, acetic acid, propionic acid, isobutyric acid, n-butyric acid, acetic anhydride, or propionic anhydride; said anhydride is acetic anhydride or propionic anhydride; said base is selected from triethylamine, pyridine, N-methylpyrrole, N-methylmorpholine, sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, sodium acetate, potassium acetate, sodium propionate, or potassium propionate.
  • said solvent I is selected from benzene, toluene, xylene, chlorobenzene, dichlorobenzene, nitro
  • Embodiment [4] A method for preparing N-acylbiphenyl alanine according to embodiment [1], characterized in that step a is carried out at a reaction temperature from 80 deg C to reflux with a reaction time of 0.5 to 48 hours.
  • Embodiment [5] A method for preparing N-acylbiphenyl alanine according to embodiment [1], characterized in that for step b, said solvent II is selected from water, ethanol, methanol, isopropanol, propanol, ethyl acetate, isopropyl acetate, ethyl propionate, acetone, butanone, methyl isobutyl ketone, tetrahydrofuran, 1,4-dioxane, N, N-dimethyl formamide, or N-methylpyrrole.
  • said solvent II is selected from water, ethanol, methanol, isopropanol, propanol, ethyl acetate, isopropyl acetate, ethyl propionate, acetone, butanone, methyl isobutyl ketone, tetrahydrofuran, 1,4-dioxane, N, N-dimethyl formamide,
  • Embodiment [6] A method for preparing N-acylbiphenyl alanine according to embodiment [1], characterized in that for step b, the weight of feed amount of said solvent II is 2 to 50 times the amount of product 1 in step a; the feed amount of said water is 0.5 to 20 times the amount of product 1 in step a.
  • Embodiment [7] A method for preparing N-acylbiphenyl alanine according to embodiment [1], characterized in that step b is carried out at a reaction temperature from room temperature to reflux.
  • Embodiment [8] A method for preparing N-acylbiphenyl alanine according to embodiment [1], characterized in that for step c, the said solvent III is selected from ethanol, methanol, ethyl acetate, N, N-dimethyl formamide, N-methylpyrrole, or tetrahydrofuran; and said palladium charcoal contains 1% to 20% palladium by weight.
  • Embodiment [9] A method for preparing N-acylbiphenyl alanine according to embodiment [1], characterized in that for step c, wherein the weight of feed amount of said solvent III is 5 to 50 times the amount of product 1 in step a, the amount of said palladium charcoal is 0.1% to 20% of the product 2 in step b by weight.
  • Embodiment [10] A method for preparing N-acylbiphenyl alanine according embodiment [1], characterized in that glacial acetic acid is also added in order to adjust pH and maintain acidic conditions while step c is carried out, and the range of reaction temperature is from 20 deg C to 150 deg C, and said pressure of hydrogen is 0.2 MPa to 10.0 MPa.
  • Alkyl being a radical or part of a radical is a straight or branched (one or, if desired and possible, more times) carbon chain, and is especially Ci-Cy-alkyl, such as Ci-C 4 -alkyl, in particular branched Ci-C 4 -alkyl, such as isopropyl.
  • the term "lower” or "C 1 -C7-" defines a moiety with up to and including maximally 7, especially up to and including maximally 4, carbon atoms, said moiety being branched (one or more times) or straight-chained and bound via a terminal or a non-terminal carbon.
  • Ci-Cy-alkyl for example, is n-pentyl, n-hexyl or n-heptyl or preferably Ci-C 4 -alkyl, especially as methyl, ethyl, n-propyl, sec-propyl, n-butyl, isobutyl, sec-butyl, tert-butyl, in particular methyl, ethyl, n-propyl, iso-propyl, n-butyl, isobutyl, sec-butyl, tert-butyl. Very preferred is methyl or ethyl.
  • Aryl as a radical or part of a radical, for example is a mono- or bicyclic aryl with 6 to 22 carbon atoms, such as phenyl, indenyl, indanyl or naphthyl, in particular phenyl.
  • reaction mixture refers to the temperature at which the reaction mixture boils, preferably a temperature up to 180 °C, preferably up to 140 °C.
  • room temperature or “ambient temperature” means a temperature of from 20 to 35 °C, such as of from 20 to 25 °C.
  • any reference to "compounds", “starting materials” and “intermediates” hereinbefore and hereinafter, is to be understood as referring also to one or more salts thereof or a mixture of a corresponding free compound, intermediate or starting material and one or more salts thereof, each of which is intended to include also any solvate, metabolic precursor such as ester or amide, or salt of any one or more of these, as appropriate and expedient and if not explicitly mentioned otherwise.
  • Different crystal forms may be obtainable and then are also included.
  • Salts can be formed where salt forming groups, such as basic or acidic groups, are present that can exist in dissociated form at least partially, e.g. in a pH range from 4 to 10 in aqueous solutions, or can be isolated especially in solid, especially crystalline, form.
  • salts may be formed preferably with organic or inorganic acids. Suitable inorganic acids are, for example, halogen acids, such as hydrochloric acid, sulfuric acid, or phosphoric acid.
  • Suitable organic acids are, for example, carboxylic, phosphonic, sulfonic or sulfamic acids, for example acetic acid, propionic acid, lactic acid, fumaric acid, succinic acid, citric acid, amino acids, such as glutamic acid or aspartic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, benzoic acid, methane- or ethane-sulfonic acid, ethane- 1 ,2-disulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, 1 ,5-naphtha- lene-disulfonic acid, N-cyclohexylsulfamic acid, N-methyl-, N-ethyl- or N-propyl-sulfamic acid, or other organic protonic acids, such as ascorbic acid.
  • carboxylic, phosphonic, sulfonic or sulfamic acids for example
  • salts may be formed with bases, e.g. metal or ammonium salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium, magnesium or calcium salts, or ammonium salts with ammonia or suitable organic amines, such as tertiary monoamines, for example triethylamine or tri(2-hydroxyethyl)amine, or heterocyclic bases, for example
  • bases e.g. metal or ammonium salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium, magnesium or calcium salts
  • ammonium salts with ammonia or suitable organic amines, such as tertiary monoamines, for example triethylamine or tri(2-hydroxyethyl)amine, or heterocyclic bases, for example
  • salts include the hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric, lactic acid, fumaric acid, succinic acid, oxalic acid, malic acid, malonic acid, tartaric acid, tolyltartaric acid, benzoyltartaric acid, orotic acid, nicotinic acid, methane-sulfonic acid or 4-methylbenzenesulfonic acid salts of compounds of formula (1), (1-a), (2), (2-a), (3), (3-a) and the like formed from reaction with the above reagents.
  • Methods to prepare acid addition salts are described in the literature, for example, in the relevant chapters of "CRC Handbook of Optical Resolutions via Diasteromeric Salt

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A novel process, novel process steps and novel intermediates useful in the synthesis of pharmaceutically active compounds, in particular neutral endopeptidase (NEP) inhibitors.

Description

PROCESS FOR MANUFACTURE OF N-ACYLBPHENYL ALANINE
Field of the invention
The invention relates to a novel process, novel process steps and novel intermediates useful in the synthesis of pharmaceutically active compounds, in particular neutral endopeptidase (NEP) inhibitors.
Background of the invention
The present invention relates to a method to prepare N-acyl derivatives of biphenyl alanine. N-acyl derivatives of biphenyl alanine are key intermediates in the synthesis of pharmaceutically active compounds, in particular neutral endopeptidase (NEP) inhibitors, such as those described in U.S. Patent No. 4,722,810, U.S. Patent No. 5,223,516, U.S. Patent No. 4,610,816, U.S. Patent No.
4,929,641, South African Patent Application 84/0670, UK 69578, U.S. Patent No. 5,217,996, EP 00342850, GB 02218983, WO 92/14706, EP 0034391 1, JP 06234754, EP 00361365, WO 90/09374, JP 07157459, WO 94/15908, U.S. Patent No. 5,273,990, U.S. Patent No. 5,294,632, U.S. Patent No. 5,250,522, EP 00636621, WO 93/09101, EP 00590442, WO 93/10773, WO2008/031567 and U.S. Patent No. 5,217,996.
Typically, synthetic methods to prepare biphenyl alanine derivatives use expensive starting materials such as non-natural D-tyrosine. Moreover, said methods require the use of trifluoromethanesulfonic anhydride, which is also expensive, to activate the phenolic hydroxyl in order to carry out the aryl coupling reaction leading to the desired biphenyl structure. One example of such a synthetic approach is described in the Journal of Medicinal Chemistry 1995, Vol. 38 No. 10. Scheme 1 illustrates one of these methods:
Figure imgf000002_0001
Scheme 1
Therefore, there is a strong need to develop inexpensive methods to prepare biphenyl alanine derivatives. It is found that the present invention meets this objective and thus provides a process that is industrially advantageous.
Summary of the invention:
This invention provides a method for preparing a N-acylbiphenyl alanine of formula (3), as defined herein. The new process, according to the present invention, for producing compounds according to formula (3), is summarized in Scheme 2. By reacting biphenyl formaldehyde, as defined herein, N-acylglycine (A), as defined herein, and an anhydride (B), as defined herein, under alkaline conditions, a compound of formula (1), as defined herein, is obtained. Said compound of formula (1) is next converted into a compound of formula (2), as defined herein, which in turn is hydrogenated, for example with hydrogen and palladium on charcoal, to provide the compound of formula (3). A compound of formula (3) can be converted into a neutral endopeptidase (NEP) inhibitors, for example, as described in the Journal of Medicinal Chemistry, 1995, Vol. 38, No. 10, 1691, and the patent documents cited hereinbefore, the disclosure for each of which is incorporated by reference
The synthetic process summarized in Scheme 2 uses inexpensive starting materials and reagents and is thus suitable for industrial production.
Figure imgf000003_0001
Scheme 2
Detailed Description of the Invention: Step a:
In a first embodiment the present invention relates to a method for preparing a compound of formula (1-a), or salt thereof,
Figure imgf000004_0001
preferably wherein the compound of formula (1-a) is of the formula (1),
Figure imgf000004_0002
wherein Rl is Ci_7alkyl, preferably methyl, or C6_ioaryl, preferably phenyl,
comprising
reacting
Figure imgf000004_0003
or salt thereof,
with
a compound of formula (A),
Figure imgf000004_0004
or salt thereof,
wherein Rl is as defined for the compound of formula (1-a),
and (R2CO)20, wherein R2 is Ci_7alkyl, preferably methyl or propyl, most preferably methyl or ethyl,
under alkaline conditions,
to provide the compound of formula (1-a). The reactions described above can be carried out in solvents generally known in the art, for example, in the presence of a solvent, (named solvent I), selected from benzene, toluene, xylene, chlorobenzene, dichlorobenzene, nitrobenzene, heptane, acetic acid, propionic acid, isobutyric acid, n-butyric acid, acetic anhydride or propionic anhydride.
Preferably, anhydride (B) is acetic anhydride or propionic anhydride.
The term "under alkaline conditions" means that the step requires a base. Preferably, said base is selected from triethylamine, pyridine, N-methylpyrrole, N-methylmorpholine, sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, sodium acetate, potassium acetate, sodium propionate, or potassium propionate.
Preferably, step a is carried out at a reaction temperature of from 80 deg C to reflux, preferably, with a reaction time of 0.5 to 48 hours.
Preferably, in step a, the molar ratio of said biphenyl formaldehyde : said N-acylglycine (A) : said anhydride (B) : said base is 1.0 : (0.7 to 5.0) : (1.0 to 6.0) : (0.05 to 2.00); the amount of said solvent I is 0 to 20 times the weight of feed amount of said biphenyl formaldehyde.
Step b:
In a further embodiment, the present invention relates to a method for preparing a compound of formula (2-a), or salt thereof,
Figure imgf000005_0001
preferably wherein the compound of formula (2-a) is of the formula (2),
Figure imgf000005_0002
wherein Rl is Ci_7alkyl, preferably methyl, or C6-ioaryl, preferably phi
comprising
reacting
a compound of formula (1-a), or salt thereof,
Figure imgf000006_0001
wherein Rl is as defined for a compound of formula (2-a),
with water
to provide the compound of formula (2-a).
The reactions described above can be carried out in solvents generally known in the art, for example, in the presence of a solvent, (named solvent II), selected from water, ethanol, methanol, isopropanol, propanol, ethyl acetate, isopropyl acetate, ethyl propionate, acetone, butanone, methyl isobutyl ketone, tetrahydrofuran, 1,4-dioxane, N, N-dimethyl formamide, or N-methylpyrrole. Preferably, the weight of feed amount of said solvent II is 2 to 50 times the amount of the compound of formula (1) [named product 1] in step a; the weight of feed amount of water is 0.5 to 20 times the amount of product 1 in step a.
Preferably, step b is carried out at a reaction temperature of from room temperature to reflux. Step c:
In a further embodiment, the present invention relates to a method for preparing a compound of formula (3), or salt thereof,
Figure imgf000007_0001
preferably wherein the compound of formula (3) is of the formula (3-a),
Figure imgf000007_0002
wherein Rl is Ci_7alkyl, preferably methyl, or C6-ioaryl, preferably phenyl, comprising
treating a compound of formula (2-a), or salt thereof,
P
Figure imgf000007_0003
preferably wherein the compound of formula (2-a) is of the formula (2),
Figure imgf000007_0004
(2) wherein Rl is Ci_7alkyl, preferably methyl, or C6-ioaryl, preferably phenyl,
under hydrogenation conditions
to provide the compound of formula (3).
Hydrogenation conditions are well-known in the art and thus refer to the use of hydrogen and a transition metal catalyst, for example, as described in Section B.3.3 in WO2009/090251, which is incorporated herein by reference. Preferably the transition metal catalyst is palladium, preferably palladium on charcoal, preferably containing 1% to 20% palladium by weight.
In another embodiment, the hydrogenation takes place with hydrogen in the presence of a transition metal catalyst comprising an organometallic complex and a chiral ligand, for example as described in Section C.2 in WO2009/090251, which is incorporated herein by reference.
The reactions described above can be carried out in solvents generally known in the art, for example, in the presence of a solvent (named solvent III) selected from ethanol, methanol, ethyl acetate, N, N-dimethyl formamide, N-methylpyrrole and tetrahydrofuran.
Preferably, in step c, the weight of feed amount of said solvent III is 5 to 50 times of the amount of the compound of formula (1) [named product 1] in step a. Preferably, the amount of palladium on charcoal is 0.1% to 20%> of the compound of formula (2) [named product 2] in step b by weight.
Preferably, in step c, glacial acetic acid is also added in order to maintain acidic conditions.
Preferably, the reaction temperature is of from 20 deg C to 150 deg C.
Preferably, the pressure of hydrogen is 0.2 MPa to 10.0 MPa.
Further embodiments:
In a further aspect, the present invention relates to a method for preparing a compound of formula (3), as defined herein, or salt thereof, comprising
i) step a), as described above;
ii) step b), as described above; and
iii) step c) as described above.
In a still further aspect, the present invention relates to a method for preparing a compound of formula (3), as defined herein, or salt thereof, comprising
iv) step b), as described above; and
v) step c) as described above.
Preferred embodiments: Embodiment [1]: A method for preparing N-acylbiphenyl alanine which is characterized by the following steps:
Wherein Rl is a straight-chain or branched-chain alkyl or aryl and R2 is a methyl or ethyl.
Embodiment [2] : A method for preparing N-acylbiphenyl alanine according to embodiment [1], characterized in that for step a, the molar ratio of said biphenyl formaldehyde: said N-acylglycine: said anhydride: said base is 1.0: (0.7 to 5.0): (1.0 to 6.0): (0.05 to 2.00), and the amount of said solvent I is 0 to 20 times the weight of feed amount of said biphenyl formaldehyde.
Embodiment [3] : A method for preparing N-acylbiphenyl alanine according to embodiment [1], characterized in that for step a, said solvent I is selected from benzene, toluene, xylene, chlorobenzene, dichlorobenzene, nitrobenzene, heptane, acetic acid, propionic acid, isobutyric acid, n-butyric acid, acetic anhydride, or propionic anhydride; said anhydride is acetic anhydride or propionic anhydride; said base is selected from triethylamine, pyridine, N-methylpyrrole, N-methylmorpholine, sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, sodium acetate, potassium acetate, sodium propionate, or potassium propionate.
Embodiment [4] : A method for preparing N-acylbiphenyl alanine according to embodiment [1], characterized in that step a is carried out at a reaction temperature from 80 deg C to reflux with a reaction time of 0.5 to 48 hours.
Embodiment [5] : A method for preparing N-acylbiphenyl alanine according to embodiment [1], characterized in that for step b, said solvent II is selected from water, ethanol, methanol, isopropanol, propanol, ethyl acetate, isopropyl acetate, ethyl propionate, acetone, butanone, methyl isobutyl ketone, tetrahydrofuran, 1,4-dioxane, N, N-dimethyl formamide, or N-methylpyrrole.
Embodiment [6] : A method for preparing N-acylbiphenyl alanine according to embodiment [1], characterized in that for step b, the weight of feed amount of said solvent II is 2 to 50 times the amount of product 1 in step a; the feed amount of said water is 0.5 to 20 times the amount of product 1 in step a.
Embodiment [7] : A method for preparing N-acylbiphenyl alanine according to embodiment [1], characterized in that step b is carried out at a reaction temperature from room temperature to reflux.
Embodiment [8] : A method for preparing N-acylbiphenyl alanine according to embodiment [1], characterized in that for step c, the said solvent III is selected from ethanol, methanol, ethyl acetate, N, N-dimethyl formamide, N-methylpyrrole, or tetrahydrofuran; and said palladium charcoal contains 1% to 20% palladium by weight.
Embodiment [9] : A method for preparing N-acylbiphenyl alanine according to embodiment [1], characterized in that for step c, wherein the weight of feed amount of said solvent III is 5 to 50 times the amount of product 1 in step a, the amount of said palladium charcoal is 0.1% to 20% of the product 2 in step b by weight.
Embodiment [10] : A method for preparing N-acylbiphenyl alanine according embodiment [1], characterized in that glacial acetic acid is also added in order to adjust pH and maintain acidic conditions while step c is carried out, and the range of reaction temperature is from 20 deg C to 150 deg C, and said pressure of hydrogen is 0.2 MPa to 10.0 MPa.
General Terms:
Listed below are definitions of various terms used to describe the present invention. These definitions, either by replacing one, more than one or all general expressions or symbols used in the present disclosure and thus yielding preferred embodiments of the invention, preferably apply to the terms as they are used throughout the specification unless they are otherwise limited in specific instances either individually or as part of a larger group.
Alkyl being a radical or part of a radical is a straight or branched (one or, if desired and possible, more times) carbon chain, and is especially Ci-Cy-alkyl, such as Ci-C4-alkyl, in particular branched Ci-C4-alkyl, such as isopropyl. The term "lower" or "C1-C7-" defines a moiety with up to and including maximally 7, especially up to and including maximally 4, carbon atoms, said moiety being branched (one or more times) or straight-chained and bound via a terminal or a non-terminal carbon. Lower or Ci-Cy-alkyl, for example, is n-pentyl, n-hexyl or n-heptyl or preferably Ci-C4-alkyl, especially as methyl, ethyl, n-propyl, sec-propyl, n-butyl, isobutyl, sec-butyl, tert-butyl, in particular methyl, ethyl, n-propyl, iso-propyl, n-butyl, isobutyl, sec-butyl, tert-butyl. Very preferred is methyl or ethyl.
Aryl, as a radical or part of a radical, for example is a mono- or bicyclic aryl with 6 to 22 carbon atoms, such as phenyl, indenyl, indanyl or naphthyl, in particular phenyl. In formulae above and below, the term " " represents a covalent bond, which comprises an (E) stereoisomer as well as a (Z) stereoisomer.
The term "reflux" refers to the temperature at which the reaction mixture boils, preferably a temperature up to 180 °C, preferably up to 140 °C.
As used herein, the term "room temperature" or "ambient temperature" means a temperature of from 20 to 35 °C, such as of from 20 to 25 °C.
The terms "transition metal catalyst", "organometallic complex" and "chiral ligand" are as described in WO2009/090251 , and said definitions are incorporated herein by reference.
In the formulae of the present application the term "Ph" means phenyl.
In view of the close relationship between the compounds and intermediates in free form and in the form of their salts, including those salts that can be used as intermediates, for example in the purification or identification of the compounds or salts thereof, any reference to "compounds", "starting materials" and "intermediates" hereinbefore and hereinafter, is to be understood as referring also to one or more salts thereof or a mixture of a corresponding free compound, intermediate or starting material and one or more salts thereof, each of which is intended to include also any solvate, metabolic precursor such as ester or amide, or salt of any one or more of these, as appropriate and expedient and if not explicitly mentioned otherwise. Different crystal forms may be obtainable and then are also included. Salts can be formed where salt forming groups, such as basic or acidic groups, are present that can exist in dissociated form at least partially, e.g. in a pH range from 4 to 10 in aqueous solutions, or can be isolated especially in solid, especially crystalline, form. In the presence of basic groups (e.g. imino or amino), salts may be formed preferably with organic or inorganic acids. Suitable inorganic acids are, for example, halogen acids, such as hydrochloric acid, sulfuric acid, or phosphoric acid. Suitable organic acids are, for example, carboxylic, phosphonic, sulfonic or sulfamic acids, for example acetic acid, propionic acid, lactic acid, fumaric acid, succinic acid, citric acid, amino acids, such as glutamic acid or aspartic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, benzoic acid, methane- or ethane-sulfonic acid, ethane- 1 ,2-disulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, 1 ,5-naphtha- lene-disulfonic acid, N-cyclohexylsulfamic acid, N-methyl-, N-ethyl- or N-propyl-sulfamic acid, or other organic protonic acids, such as ascorbic acid. In the presence of negatively charged radicals, such as carboxy or sulfo, salts may be formed with bases, e.g. metal or ammonium salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium, magnesium or calcium salts, or ammonium salts with ammonia or suitable organic amines, such as tertiary monoamines, for example triethylamine or tri(2-hydroxyethyl)amine, or heterocyclic bases, for example
N-ethyl-piperidine or Ν,Ν'-dimethylpiperazine. When a basic group and an acid group are present in the same molecule, internal salts may also be formed. Particularly useful salts include the hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric, lactic acid, fumaric acid, succinic acid, oxalic acid, malic acid, malonic acid, tartaric acid, tolyltartaric acid, benzoyltartaric acid, orotic acid, nicotinic acid, methane-sulfonic acid or 4-methylbenzenesulfonic acid salts of compounds of formula (1), (1-a), (2), (2-a), (3), (3-a) and the like formed from reaction with the above reagents. Methods to prepare acid addition salts are described in the literature, for example, in the relevant chapters of "CRC Handbook of Optical Resolutions via Diasteromeric Salt
Formation", D. Kozma, CRC Press 2002, in Acta Cryst, 2006, B62, 498-505 and in Synthesis, 2003, 13, 1965-1967.
Where the plural form is used for compounds, starting materials, intermediates, salts, pharmaceutical preparations, diseases, disorders and the like, this is intended to mean one (preferred) or more single compound(s), salt(s), pharmaceutical preparation(s), disease(s), disorder(s) or the like, where the singular or the indefinite article ("a", "an") is used, this is not intended to exclude the plural, but only preferably means "one".
Particular embodiments of the invention are provided in the following Examples. These Examples serve to illustrate the invention without limiting the scope thereof, while they on the other hand represent preferred embodiments of the reaction steps, intermediates and/or the process of the present invention.
Example 1 : Synthesis of 4-(4-biphenyl methylene)-2-methyl-oxazole-5 (4H)-ketone (1, Rl = Me)
Figure imgf000012_0001
In a dry and clean reaction bottle, add 36.4 g of biphenyl formaldehyde (Japan, Mitsubishi Chemical Co, Ltd, industrial, contents > 98%), 28 g of acetyl glycine, 56 g of acetic anhydride, and 6 g of anhydrous sodium acetate. Heat to reflux for 0.5 hours. End heat preservation and cool to 80 deg C. Add 200 ml of water and agitate for 30 min. Filtrate and use 100 ml of water to wash filter cake for two times. Vacuum dry wet product at 30 to 40 deg C to obtain the title product.
1H NMR (400 MHz, CDC13) δ 8.16 (d, J = 8.4 Hz, 2H), 7.74 - 7.66 (m, 2H), 7.66 - 7.58 (m, 2H), 7.52 - 7.43 (m, 2H), 7.43 - 7.36 (m, 1H), 7.19 (s, 1H), 2.43 (s, 3H). M=263.
Example 2: Synthesis of 2-acetamido-3 -biphenyl propenoic acid (2, Rl = Me)
Figure imgf000012_0002
In a 1000 ml reaction bottle, add 40 g of 4-(4-biphenyl methylene)-2-methyl-oxazole-5 (4H)-ketone (1, Rl = Me), 450 ml of acetone, and 60 ml of tap water. Heat to reflux for 8 hours. End heat preservation. Add 3 g activated charcoal and decolorate for 1 hour. Filtrate and wash with 50 ml of acetone. Steam distillate acetone about 300 ml and then add 200 ml of water. Cool down to 20 deg C. Filtrate and dry wet product at 60 deg C to obtain the title product. 1H NMR (400 MHz, DMSO) δ 12.69 (s, 1H), 9.53 (s, 1H), 7.81 - 7.64 (m, 6H), 7.49 (dd, J = 10.4, 4.7 Hz, 2H), 7.39 (dd, J = 8.2, 6.5 Hz, 1H), 7.26 (s, 1H), 2.01 (s, 3H). M=281,M+=280.
Example 3: Synthesis of 3-biphenyl-2-acetamido alanine acid (3, Rl = Me)
Figure imgf000013_0001
In a 1 L high-pressure autoclave, add 20 g of 2-acetamido 3-biphenyl propenoic acid(2, Rl = Me), 300 ml of anhydrous ethanol, 2 ml of glacial acetic acid, and 1 g of palladium charcoal containing 5% of palladium. Seal the reaction autoclave and use nitrogen to displace air. Heat to 70 to 80 deg C of internal temperature. Adjust hydrogen pressure to 6 MPa. React for 20 hours with heat preservation. Cool down reaction autoclave to 60 deg C. Release gas. Filtrate it. Wash with 10 ml of ethanol. Condense the filtrate to about 60 ml. Cool down to 0 to 5 deg C. Filtrate and dry wet product at 60 deg C to obtain the title product.
1H NMR (500MHz,DMSO-d6): 1.82, 2.89-2.93, 3.08-3.12, 4.45-4.50, 7.33-7.37,7.44-7.47, 7.58-7.60, 7.64-7.66, 8.26-8.28, 12.75;
MS(m/z):224.07(100),167.14(56),165.16(26),282.94([MH+],l).
Example 4: Synthesis of 4-(4-biphenyl methylene) -2-phenyl-oxazole-5(4H)-ketone (1, Rl = Ph)
Figure imgf000013_0002
In a dry and clean reaction bottle, add 36.4 g of biphenyl formaldehyde (Japan, Mitsubishi Chemical Co, Ltd, industrial, contents > 98%), 33 g of N-benzoyl glycine, 52 g of propionic anhydride, and 20 g of N-methylmorpholine and 182 g of chlorobenzene. Heat to 100 deg C. Heat preserve for 24 hours. Cool down to 80 deg C. Add 200 ml of water and agitate for 30 min. Filtrate and use 100 ml of water to wash filter cake for two times. Vacuum dry wet product to obtain the title product.
1H NMR (400 MHz, CDC13) δ 8.29 (d, J = 8.4 Hz, 2H), 8.24 - 8.17 (m, 2H), 7.73 (d, J = 8.4 Hz, 2H), 7.69 - 7.59 (m, 3H), 7.55 (t, J = 7.5 Hz, 2H), 7.49 (dd, J = 10.2, 4.8 Hz, 2H), 7.44 - 7.37 (m, 1H), 7.29 (s, 1H).M=325.
Example 5: Synthesis of 2-benzamido-3 -biphenyl propenoic acid (2, Rl = Ph)
Figure imgf000014_0001
In a 1000 ml reaction bottle, add 60 g of 4-(4-biphenyl methylene) -2-phenyl-oxazole-5 (4H)-ketone (1, Rl = Ph), 1000 ml of tetrahydrofuran, and 150ml of tap water. Heat to room temperature. Heat preserve for 24 hours. Add 3 g of activated charcoal and decolorate for 1 hour. Filtrate and wash with 50 ml of tetrahydrofuran. After steam distillating about 600ml of tetrahydrofuran, cool down to 20 deg C. Filtrate and dry wet product at 60 deg C to obtain the title product.
1H NMR (400 MHz, DMSO) δ 9.61 (s, 1H), 8.00 (t, J = 8.6 Hz, 2H), 7.82 - 7.36 (m, 13H), 7.33 (t, J = 7.2 Hz, 1H). M=343, M+=342.
Example 6: Synthesis of 3-biphenyl-2-benzamido alanine (3, Rl = Ph)
Figure imgf000014_0002
In a 1 L high-pressure autoclave, add 10 g of 2-benzamido 3-biphenyl propenoic acid (2, Rl = Ph), 350 ml of methanol, 1ml of glacial acetic acid, and 2 g of palladium charcoal (Pd/C) containing 5% of palladium. Seal the reaction autoclave and displace air with nitrogen. Heat to 140 to 150 deg C of internal temperature. Adjust nitrogen pressure to 0.2 MPa. React for 20 hours with heat preservation. Cool down reaction autoclave to 60 deg C. Release gas. Filtrate and wash with about 10 ml of ethanol. Condense filtrate to about 60 ml. Cool down to 0 to 5 deg C. Filtrate and dry wet product at 60 deg C to obtain the title product.
1H NMR (500MHz,DMSO-d6): 3.12-3.17, 3.23-3.27, 4.65-4.70, 7.31-7.33, 7.34-7.45, 7.46-7.48, 7.58-7.60, 7.62-7.64, 7.83-7.84, 8.77-8.79, 12.85;
MS(m/z):224.0(100),167.1(34),165.1(15),105.1(10),77.2(18),344.8([MH+],l).
Example 7: Synthesis of 4-(4-biphenyl methylene)-2-phenyl-oxazole-5(4H)-ketone (1, Rl = Ph)
Figure imgf000014_0003
In a dry and clean reaction bottle, add 36.4 g of biphenyl formaldehyde (Japan, Mitsubishi Chemical Co, Ltd, industrial, contents > 98%), 33 g of N-benzoyl glycine, 52 g of propionic anhydride, and 10 g of anhydrous sodium propionate and 200 g of dichlorobenzene. Heat to 80 deg C. Heat preserve for 48 hours. Cool down to 80 deg C. Add 200 ml of water and agitate for 30 min. Filtrate and use 100 ml of water to wash filter cake two times. Vacuum dry wet product at 30 to 40 deg C to obtain the title product. Spectroscopic data as Example 4.
Example 8: Synthesis of 2-benzamido-3-biphenyl propenoic acid (2, Rl
Figure imgf000015_0001
In a 1000 ml reaction bottle, add 50 g of 4-(4-biphenyl methylene)-2-phenyl-oxazole-5 (4H)-ketone (1, Rl = Ph), 550 ml of butanone, and 120 ml of tap water. Heat to 40 deg C. Heat preservation for 24 hours. Add 3 g of activated charcoal and decolorate for 1 hour. Filtrate and wash with 50 ml of tetrahydrofuran. After steam distillating about 600ml of tetrahydrofuran cool down to 20 deg C. Filtrate and dry wet product at 60 deg C to obtain the title product.
Spectroscopic data as Example 5.
Example 9: Synthesis of 3-biphenyl-2-benzamido alanine (3, Rl = Ph)
Figure imgf000015_0002
In a 1 L high-pressure autoclave, add 15 g of 2-benzamido 3-biphenyl propenoic acid (2, Rl = Ph), 300 ml of tetrahydrofuran, 1.5 ml of glacial acetic acid, and 4 g of palladium charcoal (Pd/C) containing 5% of palladium. Seal the reaction autoclave and displace air with nitrogen. Heat to 100 to 110 deg C of internal temperature. Adjust hydrogen pressure to 10.0 MPa. React for 20 hours with heat preservation. Cool down reaction autoclave to 60 deg C. Release gas. Filtrate and wash with about 10 ml of ethanol. Condense filtrate to about 60 ml. Cool down to 0 to 5 deg C. Filtrate and dry wet product at 60 deg C to obtain the title product.
Spectroscopic data as Example 6.

Claims

Claims:
1. A process for preparing a compound of formula (1-a), or salt thereof,
Figure imgf000016_0001
preferably wherein the compound of formula (1-a) is of the formula (1),
Figure imgf000016_0002
wherein Rl is Ci_7alkyl, preferably methyl, or C6_ioaryl, preferably phenyl, comprising
reacting
Figure imgf000016_0003
or salt thereof,
with
a compound of formula (A), or salt thereof,
Figure imgf000016_0004
wherein Rl is as defined for the compound of formula (1-a),
and
(R2CO)20, wherein R2 is Ci_7alkyl, preferably methyl or propyl,
under alkaline conditions,
to provide the compound of formula (1-a).
2. The process according to claim 1, wherein the alkaline conditions comprise the use of a base selected from triethylamine, pyridine, N-methylpyrrole, N-methylmorpholine, sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, sodium acetate, potassium acetate, sodium propionate and potassium propionate.
3. The process according to claim 1 or 2, wherein the reaction is carried out at a temperature of from of from 80 deg C to reflux.
4. A process for preparing a compound of formula (2-a), or salt thereof,
Figure imgf000017_0001
preferably wherein the compound of formula (2-a) is of the formula (2),
Figure imgf000017_0002
(2) wherein Rl is Ci_7alkyl, preferably methyl, or C6-ioaryl, preferably phenyl,
comprising reacting
a compound of formula (1-a), or salt thereof,
Figure imgf000018_0001
preferably wherein the compound of formula (1-a) is of the formula (1),
Figure imgf000018_0002
wherein Rl is as defined for a compound of formula (2-a),
with water
to provide the compound of formula (2-a).
5. The process according to claim 4, wherein the reaction is carried out at a temperature of from of from room temperature to reflux.
6. A process for preparing a compound of formula (3), or salt thereof,
Figure imgf000018_0003
preferably wherein the compound of formula (3) is of the formula (3-a),
Figure imgf000019_0001
wherein Rl is Ci_7alkyl, preferably methyl, or C6-ioaryl, preferably phenyl,
comprising
treating a compound of formula (2-a), or salt thereof,
Figure imgf000019_0002
preferably wherein the compound of formula (2-a) is of the formula (2),
Figure imgf000019_0003
wherein Rl is Ci_7alkyl, preferably methyl, or C6-ioaryl, preferably phenyl,
under hydrogenation conditions
to provide the compound of formula (3).
7. The process according to claim 6, wherein the hydrogenation conditions comprise the use of hydrogen and palladium, preferably, palladium on charcoal.
8. A process for preparing a compound of formula (3), as defined in claim 6,
comprising the steps of
i) preparing the compound of formula (1-a), as defined in claim 1, according to any one of the processes defined in claims 1 to 3, preferably according to the process defined in claim 1;
ii) preparing the compound of formula (2-a), as defined in claim 4, according to the process defined in claim 4 or 5, preferably according to the process defined in claim 4; and
iii) obtaining the compound of formula (3), according to the process defined in claim 6 or 7.
9. A process for preparing a compound of formula (3), as defined in claim 6,
comprising the steps of
ii) preparing the compound of formula (2-a), as defined in claim 4, according to the process defined in claim 4 or 5, preferably according to the process defined in claim 4; and
iii) obtaining the compound of formula (3), according to the process defined in claim 6 or 7.
10. A compound of formula (1-a), or salt thereof,
Figure imgf000020_0001
preferably wherein the compound of formula (1-a) is of the formula (1),
Figure imgf000020_0002
wherein Rl is Ci_7alkyl, preferably methyl, or C6_ioaryl, preferably phenyl.
11. A compound of formula (2-a), or salt thereof,
Figure imgf000021_0001
preferably wherein the compound of formula (2-a) is of the formula (2),
Figure imgf000021_0002
wherein Rl is Ci_7alkyl, preferably methyl, or C6-ioaryl, preferably phenyl.
12. A compound of formula (3), or salt thereof,
Figure imgf000021_0003
preferably wherein the compound of formula (3) is of the formula (3-a),
Figure imgf000022_0001
wherein Rl is Ci.7alkyl, preferably methyl, or Q-ioaryl, preferably phenyl.
PCT/CN2010/071243 2008-09-24 2010-03-23 Process for manufacture of n-acylbphenyl alanine WO2011035569A1 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
US13/497,544 US20130172572A1 (en) 2008-09-24 2010-03-23 Process for Manufacture of N-acylbiphenyl alanine
CN201080042243.1A CN102639486B (en) 2009-09-23 2010-03-23 Process for manufacture of N-acylbphenyl alanine
IN1968DEN2012 IN2012DN01968A (en) 2009-09-23 2010-03-23
AU2010297892A AU2010297892B2 (en) 2009-09-23 2010-03-23 Process for manufacture of N-acylbphenyl alanine
CA2772681A CA2772681C (en) 2009-09-23 2010-03-23 Process for manufacture of n-acylbphenyl alanine
KR1020167036201A KR101821090B1 (en) 2009-09-23 2010-03-23 Process for manufacture of n-acylbiphenyl alanine
ES10818263.5T ES2627060T3 (en) 2008-09-24 2010-03-23 Process for the elaboration of N-acyl-biphenyl-alanine
MX2012003488A MX2012003488A (en) 2008-09-24 2010-03-23 Process for manufacture of n-acylbphenyl alanine.
EP10818263.5A EP2480523B1 (en) 2009-09-23 2010-03-23 Process for manufacture of n-acylbphenyl alanine
JP2012530106A JP5894531B2 (en) 2009-09-23 2010-03-23 Process for producing N-acylbiphenylalanine
RU2012116208/04A RU2534619C2 (en) 2009-09-23 2010-03-23 Method of obtaining n-acylbiphenylalanine
BR112012006406A BR112012006406A2 (en) 2009-09-23 2010-03-23 "Process for the manufacture of n-acylbiphenyl alanine"
US14/163,526 US9242927B2 (en) 2008-09-24 2014-01-24 Process for the manufacture of N-acylbiphenyl alanine
US14/990,832 US20160115118A1 (en) 2009-09-23 2016-01-08 Process for the manufacture of n-acylbiphenyl alanine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNPCT/CN2009/074125 2009-09-23
PCT/CN2009/074125 WO2010034236A1 (en) 2008-09-24 2009-09-23 Process for the manufacture of n-acylbiphenyl alanine

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US13/497,544 A-371-Of-International US20130172572A1 (en) 2008-09-24 2010-03-23 Process for Manufacture of N-acylbiphenyl alanine
US13497544 A-371-Of-International 2012-03-22
US14/163,526 Continuation US9242927B2 (en) 2008-09-24 2014-01-24 Process for the manufacture of N-acylbiphenyl alanine

Publications (1)

Publication Number Publication Date
WO2011035569A1 true WO2011035569A1 (en) 2011-03-31

Family

ID=43796233

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2010/071243 WO2011035569A1 (en) 2008-09-24 2010-03-23 Process for manufacture of n-acylbphenyl alanine

Country Status (11)

Country Link
US (1) US20160115118A1 (en)
EP (1) EP2480523B1 (en)
JP (1) JP5894531B2 (en)
KR (2) KR101821090B1 (en)
CN (1) CN102639486B (en)
AU (1) AU2010297892B2 (en)
BR (1) BR112012006406A2 (en)
CA (1) CA2772681C (en)
IN (1) IN2012DN01968A (en)
RU (1) RU2534619C2 (en)
WO (1) WO2011035569A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8222286B2 (en) 2009-11-20 2012-07-17 Novartis Ag Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors
US8263629B2 (en) 2009-05-28 2012-09-11 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors
US8394853B2 (en) 2009-05-28 2013-03-12 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
US9102635B2 (en) 2013-02-14 2015-08-11 Novartis Ag Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo efficacy
US9163040B2 (en) 2013-02-14 2015-10-20 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors
WO2016128924A1 (en) 2015-02-13 2016-08-18 Novartis Ag Process and intermediates for the preparation of nep inhibitors
WO2017051326A1 (en) 2015-09-23 2017-03-30 Novartis Ag New processes and intermediates useful in synthesis of nep inhibitors
WO2017098430A1 (en) 2015-12-10 2017-06-15 Novartis Ag New process and intermediates
WO2018007919A1 (en) 2016-07-05 2018-01-11 Novartis Ag New process for early sacubitril intermediates
WO2018033866A1 (en) 2016-08-17 2018-02-22 Novartis Ag New processes and intermediates for nep inhibitor synthesis
WO2018116203A1 (en) 2016-12-23 2018-06-28 Novartis Ag New process for early sacubitril intermediates
US10668035B2 (en) 2018-02-07 2020-06-02 Novartis Ag Substituted bisphenyl butanoic ester derivatives as NEP inhibitors

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107778192A (en) * 2016-08-26 2018-03-09 浙江九洲药业股份有限公司 A kind of preparation method of N alcoxyls or benzyloxycarbonyl group chirality propylhomoserin

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0212617A1 (en) * 1985-08-23 1987-03-04 Lederle (Japan) Ltd. Process for producing 4-biphenylylacetic acid
WO2004002977A1 (en) * 2002-07-01 2004-01-08 Pharmacia & Upjohn Company Llc Inhibitors of hcv ns5b polymerase
US20040180943A1 (en) * 2002-07-23 2004-09-16 Augelli-Szafran Corinne Elizabeth Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis
WO2009090251A2 (en) 2008-01-17 2009-07-23 Novartis Ag New processes
CN101684077A (en) * 2008-09-24 2010-03-31 浙江九洲药业股份有限公司 Method for preparing N-acyl diphenylalanine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60185752A (en) * 1984-03-05 1985-09-21 Mitsui Toatsu Chem Inc Production of alpha-acetamidocinnamic acid
JPS60215657A (en) * 1984-04-10 1985-10-29 Mitsui Toatsu Chem Inc Preparation of n-acylphenylalanine
JPS6245554A (en) * 1985-08-23 1987-02-27 Nippon Redarii Kk Simple production of 4-biphenylylacetic acid
FR2662440B1 (en) * 1990-05-22 1992-07-31 Rhone Poulenc Sante PROCESS FOR THE STEREOSELECTIVE PREPARATION OF PHENYLISOSERIN DERIVATIVES.
IL123986A (en) * 1997-04-24 2011-10-31 Organon Nv Serine protease inhibiting antithrombotic agents and pharmaceutical compositions comprising them
GB2354440A (en) * 1999-07-20 2001-03-28 Merck & Co Inc Aryl amides as cell adhesion inhibitors
JP4270484B2 (en) * 2002-03-08 2009-06-03 第一ファインケミカル株式会社 Method for producing optically active phenylalanine derivative
CN101774941A (en) * 2009-01-13 2010-07-14 浙江九洲药业股份有限公司 Method for preparing and splitting 2-acyl amino-3-biphenylyl propionic acid
CN101555211B (en) * 2009-05-13 2012-01-25 浙江九洲药业股份有限公司 Chemical synthesis method of 2-acylamino-3-biphenyl propionic acid

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0212617A1 (en) * 1985-08-23 1987-03-04 Lederle (Japan) Ltd. Process for producing 4-biphenylylacetic acid
WO2004002977A1 (en) * 2002-07-01 2004-01-08 Pharmacia & Upjohn Company Llc Inhibitors of hcv ns5b polymerase
US20040180943A1 (en) * 2002-07-23 2004-09-16 Augelli-Szafran Corinne Elizabeth Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis
WO2009090251A2 (en) 2008-01-17 2009-07-23 Novartis Ag New processes
CN101684077A (en) * 2008-09-24 2010-03-31 浙江九洲药业股份有限公司 Method for preparing N-acyl diphenylalanine

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE DATABASE [online] CHEMICAL ABSTRACTS SERVICE; 6 October 1989 (1989-10-06), "4-([1,1'-biphenyl]-4-ylmethylene)-2-methyl-5(4H)-oxazolone", XP008154887, accession no. STN Database accession no. 909768-56-5 *
GARY M. K. ET AL.: "Dicarboxylic acid dipeptide neutral endopeptidase inhibitors.", J. MED. CHEM., vol. 38, no. 10, May 1995 (1995-05-01), pages 1689 - 1700, XP008154341 *
JOURNAL OF MEDICINAL CHEMISTRY, vol. 38, no. 10, 1995, pages 1691
KHAN, KHALID MOHAMMED ET AL.: "Synthesis and antibacterial and antifungal activity of 5-substituted imidazolones.", LETTERS IN DRUG DESIGN & DISCOVERY, vol. 6, no. 1, January 2009 (2009-01-01), pages 69 - 77, XP008154334 *
PETKOVA, IRINA ET AL.: "Tuning the excited-state dynamics of GFP-inspired imidazolone derivatives.", J. PHYS. CHEM. A, vol. 114, 12 November 2009 (2009-11-12), pages 10 - 20, XP008154345 *
See also references of EP2480523A4

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263629B2 (en) 2009-05-28 2012-09-11 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors
US8394853B2 (en) 2009-05-28 2013-03-12 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
US9006249B2 (en) 2009-05-28 2015-04-14 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors
US9603819B2 (en) 2009-05-28 2017-03-28 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors
US8222286B2 (en) 2009-11-20 2012-07-17 Novartis Ag Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors
US8377978B2 (en) 2009-11-20 2013-02-19 Novartis Ag Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors
US8642635B2 (en) 2009-11-20 2014-02-04 Novartis Ag Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors
US8877786B2 (en) 2009-11-20 2014-11-04 Novartis Ag Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors
US9480693B2 (en) 2013-02-14 2016-11-01 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors
US9163040B2 (en) 2013-02-14 2015-10-20 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors
US9102635B2 (en) 2013-02-14 2015-08-11 Novartis Ag Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo efficacy
US10112963B2 (en) 2013-02-14 2018-10-30 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors
WO2016128924A1 (en) 2015-02-13 2016-08-18 Novartis Ag Process and intermediates for the preparation of nep inhibitors
WO2017051326A1 (en) 2015-09-23 2017-03-30 Novartis Ag New processes and intermediates useful in synthesis of nep inhibitors
WO2017098430A1 (en) 2015-12-10 2017-06-15 Novartis Ag New process and intermediates
US11434192B2 (en) 2015-12-10 2022-09-06 Novartis Ag Process and intermediates
WO2018007919A1 (en) 2016-07-05 2018-01-11 Novartis Ag New process for early sacubitril intermediates
WO2018033866A1 (en) 2016-08-17 2018-02-22 Novartis Ag New processes and intermediates for nep inhibitor synthesis
WO2018116203A1 (en) 2016-12-23 2018-06-28 Novartis Ag New process for early sacubitril intermediates
US10668035B2 (en) 2018-02-07 2020-06-02 Novartis Ag Substituted bisphenyl butanoic ester derivatives as NEP inhibitors
US11426375B2 (en) 2018-02-07 2022-08-30 Novartis Ag Substituted bisphenyl butanoic ester derivatives as NEP inhibitors

Also Published As

Publication number Publication date
AU2010297892A1 (en) 2012-03-22
JP2013505273A (en) 2013-02-14
EP2480523A4 (en) 2013-06-26
CA2772681C (en) 2017-01-03
KR20120093227A (en) 2012-08-22
EP2480523A1 (en) 2012-08-01
CA2772681A1 (en) 2011-03-31
RU2534619C2 (en) 2014-11-27
IN2012DN01968A (en) 2015-08-21
JP5894531B2 (en) 2016-03-30
CN102639486B (en) 2014-12-31
KR101821090B1 (en) 2018-01-22
EP2480523B1 (en) 2017-03-01
CN102639486A (en) 2012-08-15
BR112012006406A2 (en) 2016-04-12
KR20170002681A (en) 2017-01-06
US20160115118A1 (en) 2016-04-28
AU2010297892B2 (en) 2014-02-06
RU2012116208A (en) 2013-11-10

Similar Documents

Publication Publication Date Title
EP2480523B1 (en) Process for manufacture of n-acylbphenyl alanine
US9242927B2 (en) Process for the manufacture of N-acylbiphenyl alanine
CA2749092C (en) Process for manufacture and resolution of 2-acylamino-3-diphenylpropanoic acid
TW201502124A (en) Method for preparation of benzimidazole derivatives
JP2009173621A (en) Method for producing 2-amino-n-(2,2,2,-trifluoroethyl)acetamide compound or salt thereof
MXPA04001837A (en) Processes for the production of alpha-difluoromethyl ornithine (dfmo).
EP2032581B1 (en) Enantiomerically enriched compounds and process
CA2910011A1 (en) A process for preparing ivabradine
TWI719620B (en) 6-AMINOPYRAZOLO[3,4-d]PYRIMIDINES AND PROCESSES FOR THEIR PREPARATION
CN112457258A (en) Preparation method of oxalaggrin sodium and intermediate thereof
WO2012069423A1 (en) Method for the preparation of naproxen chloride
EP2152697A2 (en) Process for the preparation of alfuzosin and salts thereof
WO2013054273A2 (en) Process for the preparation of agomelatine
JP2011515328A (en) Efficient method for producing atorvastatin
WO2006082835A1 (en) Method for producing theanine
CN101955464A (en) 4-(4-methoxybenzylamino)-3-(5-nitro-4-thiocyanic acid pyrimidine-2-amino) benzonitrile, preparation method and application thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080042243.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10818263

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010297892

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2772681

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1968/DELNP/2012

Country of ref document: IN

REEP Request for entry into the european phase

Ref document number: 2010818263

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010818263

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2010297892

Country of ref document: AU

Date of ref document: 20100323

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012530106

Country of ref document: JP

Ref document number: 13497544

Country of ref document: US

Ref document number: MX/A/2012/003488

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20127010180

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012116208

Country of ref document: RU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012006406

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012006406

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120321